Transgene S.A. Patent applications |
Patent application number | Title | Published |
20150017126 | POXVIRAL ONCOLYTIC VECTORS - The present invention relates to a poxvirus comprising a defective F4L and/or I4L gene, to composition comprising such poxvirus and to the methods and use of such compositions and poxviruses for therapeutic purposes, and more particularly for the treatment of cancer. | 01-15-2015 |
20140287480 | HBV POLYMERASE MUTANTS - The present invention relates to polymerase HBV mutant polypeptides comprising a mutated polymerase domain which is functionally disrupted for polymerase activity and fusion proteins comprising such polymerase mutant polypeptide. The present invention also relates to a nucleic acid molecule and an expression vector for expressing said polymerase mutant polypeptide as well as a composition which can be used for eliciting an immune response to HBV with the goal of providing a protective or therapeutic effect against HBV infection. | 09-25-2014 |
20140141039 | Biomarker for Monitoring Patients - The present invention is in the field of immunotherapy and relates to methods for determining the efficacy of certain immunotherapy treatments. The methods of the invention include measuring special biomarker at some time following the initiation of immunotherapy treatment to evaluate the clinical outcome of the said treatment. The invention thus has applications to the field of medicine. | 05-22-2014 |
20140086958 | Biomarker for Selecting Patients and Related Methods - The present invention concerns methods for inducing an immune response to an antigen in a patient for treating human disease by administering an immunogenic composition wherein said patient is selected in a patient population of interest. The present invention further concerns methods for determining whether a subject is or is not susceptible to developing a prophylactic or therapeutic immune response after such treatment. | 03-27-2014 |
20140073033 | METHOD FOR ORTHOPOXVIRUS PRODUCTION AND PURIFICATION - The present invention relates to a method for producing and purifying a wild type, an attenuated and/or a recombinant | 03-13-2014 |
20140057972 | ANTIBODY AGAINST THE CSF-1R - The present invention provides antibodies specific for the CSF-1R, compositions comprising said antibodies and methods of treatment using such compositions. | 02-27-2014 |
20140023686 | SOLUBLE ICAM-1 AS BIOMARKER FOR PREDICTION OF THERAPEUTIC RESPONSE - The present invention relates to the field of immunology and, in particular, to a vaccination procedure for treatment of a patient against diseases caused for example by infection or cancers. More particularly, the invention relates to methods for predicting whether a subject is or is not susceptible to developing a prophylactic or therapeutic response, preferably immune response, after such vaccination. The present invention relates to methods and compositions for selecting patients best able to raise a therapeutic immune response in vivo by an immunogenic composition, in particular a vaccine. | 01-23-2014 |
20130289250 | ANTIBODY AGAINST THE CFR-1R - The present invention provides antibodies specific for the CSF-1R, compositions comprising said antibodies and methods of treatment using such compositions. | 10-31-2013 |
20130287737 | Poxviral Oncolytic Vectors - The present invention relates to a poxvirus comprising a defective F4L and/or I4L gene, to composition comprising such poxvirus and to the methods and use of such compositions and poxviruses for therapeutic purposes, and more particularly for the treatment of cancer. | 10-31-2013 |
20130244246 | IMMORTALIZED AVIAN CELL LINES COMPRISING E1A NUCLEIC ACID SEQUENCES - This invention relates to immortalized avian cells, and to the use of these cells for the production of viruses. The cells according to the invention are particularly useful for the production of recombinant viral vectors which can be used for the preparation of therapeutic and/or prophylactic compositions for the treatment of animals and more particularly humans. | 09-19-2013 |
20130236929 | IMMORTALIZED AVIAN CELL LINES AND USE THEREOF - The present invention relates to specific immortalized avian cell lines expressing telomerase reverse transcriptase (TERT), and exhibiting distinct biologics production patterns. More particularly, the present invention relates to immortalized avian cell line capable of either amplifying Flaviviridae but not capable of amplifying Vaccinia virus strain Copenhagen (VV-COP) nor Modified Vaccinia virus Ankara (MVA), or capable of amplifying both Flaviviridae and Poxviridae. The invention further relates to the use of said immortalized avian cell lines and related methods for producing biologics, including viruses and proteins. | 09-12-2013 |
20130095557 | IMMORTALIZED AVIAN CELL LINES - This invention relates to immortalized avian cells, including those deposited under accession numbers 09070701, 09070702, and 09070703 at the ECACC, and to the use of these cells for the production of viruses. The cells according to the invention are particularly useful for the production of recombinant viral vectors which can be used for the preparation of therapeutic and/or prophylactic compositions for the treatment of animals and more particularly humans. | 04-18-2013 |
20130084620 | PROCESS FOR PRODUCING POXVIRUSES AND POXVIRUS COMPOSITIONS - The present invention relates to compositions and pharmaceutical compositions comprising poxviruses and more particularly extracellular enveloped viruses. The present invention also relates to a process for producing poxviruses and poxviruses obtained thereof. Moreover, the present invention also relates to the use of said poxvirus and said composition for the preparation of a medicament. | 04-04-2013 |
20130039891 | POXVIRAL ONCOLYTIC VECTORS - The present invention relates to a poxvirus comprising a defective F4L and/or I4L gene, to composition comprising such poxvirus and to the methods and use of such compositions and poxviruses for therapeutic purposes, and more particularly for the treatment of cancer. | 02-14-2013 |
20130011435 | COMPOSITION FOR TREATING HBV INFECTION - The present invention provides a composition comprising hepatitis B virus (HBV) component(s), and which may be either nucleic acid- or polypeptide-based as well as nucleic acid molecules and vectors encoding such HBV component(s). It also relates to infectious viral particles and host cells comprising such nucleic acid molecules or vectors. It also provides composition and kits of parts comprising such nucleic acid molecules, vectors, infectious viral particles or host cells and the therapeutic use thereof for preventing or treating HBV infections. | 01-10-2013 |
20120276614 | PROCESS FOR PRODUCING POXVIRUSES AND POXVIRUS COMPOSITIONS - The present invention relates to compositions and pharmaceutical compositions comprising poxviruses and more particularly extracellular enveloped viruses. The present invention also relates to a process for producing poxviruses and poxviruses obtained thereof. Moreover, the present invention also relates to the use of said poxvirus and said composition for the preparation of a medicament. | 11-01-2012 |
20120251569 | COMPOSITION FOR TREATING HBV INFECTION - The present invention provides a composition comprising hepatitis B virus (HBV) component(s), and which may be either nucleic acid- or polypeptide-based as well as nucleic acid molecules and vectors encoding such HBV component(s). It also relates to infectious viral particles and host cells comprising such nucleic acid molecules or vectors. It also provides composition and kits of parts comprising such nucleic acid molecules, vectors, infectious viral particles or host cells and the therapeutic use thereof for preventing or treating HBV infections. | 10-04-2012 |
20120238000 | IMMORTALIZED AVIAN CELL LINES - This invention relates to immortalized avian cells, including those deposited under accession numbers 09070701, 09070702, and 09070703 at the ECACC, and to the use of these cells for the production of viruses. The cells according to the invention are particularly useful for the production of recombinant viral vectors which can be used for the preparation of therapeutic and/or prophylactic compositions for the treatment of animals and more particularly humans. | 09-20-2012 |
20120122155 | IMMORTALIZED AVIAN CELL LINES AND USE THEREOF - The present invention relates to specific immortalized avian cell lines expressing telomerase reverse transcriptase (TERT), and exhibiting distinct biologics production patterns. More particularly, the present invention relates to immortalized avian cell line capable of either amplifying Flaviviridae but not capable of amplifying Vaccinia virus strain Copenhagen (W—COP) nor Modified Vaccinia virus Ankara (MVA), or capable of amplifying both Flaviviridae and Poxviridae. The invention further relates to the use of said immortalized avian cell lines and related methods for producing biologics, including viruses and proteins. | 05-17-2012 |
20120093780 | PROCESS FOR PRODUCING POXVIRUSES AND POXVIRUS COMPOSITIONS - The present invention relates to compositions and pharmaceutical compositions comprising poxviruses and more particularly extracellular enveloped viruses. The present invention also relates to a process for producing poxviruses and poxviruses obtained thereof. Moreover, the present invention also relates to the use of said poxvirus and said composition for the preparation of a medicament. | 04-19-2012 |
20120058539 | METHOD FOR ORTHOPOXVIRUS PRODUCTION AND PURIFICATION - The present invention relates to a method for producing and purifying a wild type, an attenuated and/or a recombinant Orthopoxvirus. The present invention relates to a purified wild type, attenuated and/or recombinant Orthopoxvirus obtained by the method of the invention and to a pharmaceutical composition, preferably a vaccine, comprising said purified Orthopoxvirus for the treatment and/or the prevention a cancer, an infectious disease and/or an autoimmune disorder, and uses thereof. The present invention also relates to the use of an immortalized avian cell line obtained from an avian cell belonging to the Anatidae family, in particular | 03-08-2012 |
20120039938 | COMPOSITION COMPRISING THE POLYPROTEIN NS3/NS4 AND THE POLYPEPTIDE NS5B OF HCV, EXPRESSION VECTORS INCLUDING THE CORRESPONDING NUCLEIC SEQUENCES AND THEIR THERAPEUTIC USE - The invention relates to a peptidic compound containing a polyprotein NS3/NS4 of a hepatitis C virus and a polypeptide NS5b of hepatitis C virus. Said invention also relates to expression vectors such as adenovirus and poxyvirus in which nucleic sequences coding for the polyprotein NS3/NS4 and the polypeptide NS5b. The inventive compound can be used for a therapeutic application. | 02-16-2012 |
20110212488 | IMMORTALIZED AVIAN CELL LINES AND USE THEREOF - The present invention relates to specific immortalized avian cell lines expressing telomerase reverse transcriptase (TERT), and exhibiting distinct biologics production patterns. More particularly, the present invention relates to immortalized avian cell line capable of either amplifying Flaviviridae but not capable of amplifying Vaccinia virus strain Copenhagen (W—COP) nor Modified Vaccinia virus Ankara (MVA), or capable of amplifying both Flaviviridae and Poxyiridae. The invention further relates to the use of said immortalized avian cell lines and related methods for producing biologics, including viruses and proteins. | 09-01-2011 |
20110008872 | Immortalized Avian Cell Lines - This invention relates to immortalized avian cells, including those deposited under accession numbers 09070701, 09070702, and 09070703 at the ECACC, and to the use of these cells for the production of viruses. The cells according to the invention are particularly useful for the production of recombinant viral vectors which can be used for the preparation of therapeutic and/or prophylactic compositions for the treatment of animals and more particularly humans. | 01-13-2011 |
20100330051 | POLYPEPTIDE HAVING AN IMPROVED CYTOSINE DEAMINASE ACTIVITY - The present invention relates to a polypeptide possessing a CDase activity, characterized in that it is derived from a native CDase by addition of an amino acid sequence with the proviso that said polypeptide has no UPRtase or Thymidine Kinase activity. | 12-30-2010 |
20100330031 | POLYPEPTIDE HAVING AN IMPROVED CYTOSINE DEAMINASE ACTIVITY - The present invention relates to a polypeptide possessing a CDase activity, characterized in that it is derived from a native CDase by addition of an amino acid sequence with the proviso that said polypeptide has no UPRtase or Thymidine Kinase activity. | 12-30-2010 |
20100303838 | VECTORS FOR MULTIPLE GENE EXPRESSION - The present invention provides a vector for expressing at least a first and a second nucleic acid molecules which exhibit a percentage of homology of approximately 80% or greater than 80% over a portion of 40 or more continuous nucleotides and wherein said first nucleic acid molecule and/or said second nucleic acid molecule is modified so as to reduce said percentage of homology to less than 75%. The present invention also relates to substantially isolated nucleic acid molecules comprising a nucleotide sequence as defined in any of SEQ ID NO: 9-15 and 66-69. It also provides a host cell and a pharmaceutical composition comprising such a nucleic acid molecule or vector as well as their use for therapeutic or preventive purposes. | 12-02-2010 |
20100255501 | METHOD OF IDENTIFYING A MHC CLASS I RESTRICTED T CELL RESPONSE - Described are peptides and polypeptides derived from the MUC-1 polypeptide which are able to activate Cytotoxic T Lymphocyte (CTL) response, analogues of such peptides and polypeptides nucleotide sequences encoding such peptides and polypeptides and therapeutic uses thereof. Moreover, indications for selecting appropriate minimal antigenic MUC-1 polypeptides with reference to the HLA-type of the patient to be treated or tested are described. | 10-07-2010 |
20100196324 | MULTIFUNCTIONAL CYTOKINES - The present invention relates to a novel fusion protein with the formula X-Y, or Y-X, wherein X represents a first immunoregulating polypeptide and Y represents a second immunoregulating polypeptide different from X. The present invention also relates to a nucleic acid molecule encoding such a fusion protein and a vector comprising such a nucleic acid molecule. The present invention also provides infectious viral particles and host cells comprising such a nucleic acid molecule or such a vector as well as a process for producing such infectious viral particles. The present invention also relates to a method for recombinantly producing such a fusion protein. Finally, the present invention also provides a pharmaceutical composition comprising such a fusion protein, a nucleic acid molecule, a vector, infectious viral particles and a host cell as well as the therapeutic use thereof. | 08-05-2010 |
20100173378 | AVIAN TELOMERASE REVERSE TRANSCIPTASE - The present invention notably relates to novel recombinant telomerase reverse transcriptases, nucleic acid molecules coding them, cells comprising said nucleic acid molecule and use of these cells for the production of substance of interest. | 07-08-2010 |
20100160227 | SIGNALING PEPTIDES - The present invention provides novel peptides of specified sequence and their use as a signal peptide or a membrane-anchoring peptide. It also relates to chimeric polypeptide comprising one or more such peptides and a polypeptide of interest as well as nucleic acid molecules, vectors, infections vital particles and host cells encoding such peptides and chimeric polypeptides. The present invention also relates to a pharmaceutical composition comprising such elements and a pharmaceutically acceptable vehicle. The present invention also provides a method for recumbently producing a polypeptide using such peptides, especially for directing expression of a polypeptide of interest extracellularly or anchored at the surface of the plasma membrane. | 06-24-2010 |
20100129403 | RECOMBINANT VIRAL VACCINE - The present invention concerns new recombinant viral vaccines. In particular the present invention provides combination products that comprise recombinant viral vectors and specific compounds able to improve the immune response raised in vivo by said recombinant viral vectors. | 05-27-2010 |
20100074869 | Multifunctional Cytokines - The present invention relates to a novel fusion protein with the formula X-Y, or Y-X, wherein X represents a first immunoregulating polypeptide and Y represents a second immunoregulating polypeptide different from X. The present invention also relates to a nucleic acid molecule encoding such a fusion protein and a vector comprising such a nucleic acid molecule. The present invention also provides infectious viral particles and host cells comprising such a nucleic acid molecule or such a vector as well as a process for producing such infectious viral particles. The present invention also relates to a method for recombinantly producing such a fusion protein. Finally, the present invention also provides a pharmaceutical composition comprising such a fusion protein, a nucleic acid molecule, a vector, infectious viral particles and a host cell as well as the therapeutic use thereof. | 03-25-2010 |
20100061957 | HPV-16-BASED PAPILLOMAVIRUS VACCINES - Compositions containing one or more early polypeptide(s) of human papillomavirus (HPV)-16 or a nucleic acid encoding one or more early polypeptide(s) of HPV-16 are useful for preventing or treating an infection or a pathological condition caused by at least one papillomavirus other than HPV-16; the subject compositions are of very special interest in immunotherapy, in particular for preventing or treating HPV persistent infections that might promote cervical intraepithelial neoplasia (CIN) and ultimately cervical cancer. | 03-11-2010 |
20100055069 | HPV-18-BASED PAPILLOMAVIRUS VACCINES - Compositions containing one or more early polypeptide(s) of human papillomavirus (HPV)-18 or a nucleic acid encoding one or more early polypeptide(s) of HPV-18 are useful for preventing or treating an infection or a pathological condition caused by at least one papillomavirus other than HPV-18; the subject compositions are of very special interest in immunotherapy, in particular for preventing or treating HPV persistent infections that might promote cervical intraepithelial neoplasia (CIN) and ultimately cervical cancer. | 03-04-2010 |
20100008941 | COMPOSITION COMPRISING THE POLYPROTEIN NS3/NS4 AND THE POLYPEPTIDE NS5B OF HCV, EXPRESSION VECTORS INCLUDING THE CORRESPONDING NUCLEIC SEQUENCES AND THEIR THERAPEUTIC USE - The invention relates to a peptidic compound containing a polyprotein NS3/NS4 of a hepatitis C virus and a polypeptide NS5 | 01-14-2010 |
20090317422 | USE OF PPD FOR THE ADJUVANTATION OF A NUCLEIC ACID VACCINE - The present invention provides a novel adjuvant for nucleic acid vaccines, and in particular the present invention provides nucleic acid vaccines that comprise, or are administered in association with PPD. The present invention also provides methods to improve the therapeutic efficacy of nucleic acid vaccines. | 12-24-2009 |
20090186046 | Hepatitis C Virus Non Structural Fusion Protein - The present invention relates to an isolated fusion protein comprising at least three NS polypeptides originating from a hepatitis C virus which are configured in said fusion protein in an order which is distinct of the order in which they appear in the native configuration. The present invention also relates to a nucleic acid molecule encoding such a fusion protein and a vector comprising such a nucleic acid molecule. The present invention also provides infectious viral particles and host cells comprising such a nucleic acid molecule or such a vector. The present invention also relates to a method for recombinantly producing such a fusion protein. Finally, the present invention also provides a pharmaceutical composition comprising such a fusion protein, a nucleic acid molecule, a vector, infectious viral particles and a host cell as well as the therapeutic use thereof for treating or preventing HCV infections, HCV-associated diseases and pathologic conditions as well as a method of inducing or stimulating an immune response against HCV in a host organism. | 07-23-2009 |
20090170795 | Kit of parts designed for implementing an antitumoral or antiviral treatment in a mammal - The present invention relates to a kit of parts comprising a nucleic acid sequence encoding a permease and a drug comprising one nucleobase moiety or a precursor thereof. The present invention further relates to a kit of parts comprising a precursor of a drug comprising a gene coding a permease and a nucleic acid sequence comprising a suicide gene. The present invention also relates to a vector comprising a gene coding a permease and a suicide gene. | 07-02-2009 |
20090104156 | PHARMACEUTICAL COMPOSITIONS FOR TREATING PAPILLOMAVIRUS TUMORS AND INFECTION - A pharmaceutical composition for treating or preventing a papillomavirus infection or tumour, including, as the therapeutical agents, a polypeptide from an early region and a polypeptide from a late region of a papillomavirus, optionally combined with a polypeptide having immunostimulatory activity or a polypeptide from an early or late region of a papillomavirus and a polypeptide having immunostimulatory activity, or alternatively, a recombinant vector containing inserted DNA fragments coding for the above-mentioned polypeptide combinations. | 04-23-2009 |
20090087449 | Novel Peptide Compositions and the Use Thereof, in Particular, in the Preparation of Active Pharmaceutical Compositions Against the Hepatitis C Virus - The invention relates to novel peptide compositions. In particular, the invention relates to a peptide composition comprising at least two peptides which are selected from among the following peptides: a peptide A having at least the amino acid sequence of SEQ ID NO 1, a peptide B having at least the amino acid sequence of SEQ ID NO 45, a peptide C having at least the amino acid sequence of SEQ ID NO 127, and a peptide D having at least the amino acid sequence of SEQ ID NO 174. The inventive compositions can be used, in particular, in the preparation of active pharmaceutical compositions against the hepatitis C virus. | 04-02-2009 |
20090075879 | Novel Peptide Compositions and the Use Thereof, in Particular, in the Preparation of Active Pharmaceutical Compositions Against the Hepatitis C Virus - The invention relates to novel peptide compositions. In particular, the invention relates to a peptide composition comprising at least two peptides which are selected from among the following peptides: a peptide A having at least the amino acid sequence of SEQ ID No1, a peptide B having at least the amino acid sequence of SEQ ID No45, a peptide C having at least the amino acid sequence of SEQ ID No127, and a peptide D having at least the amino acid sequence of SEQ ID No 174. The inventive compositions can be used, in particular, in the preparation of active pharmaceutical compositions against the hepatitis C virus. | 03-19-2009 |
20080227082 | METHOD OF IDENTIFYING A MHC CLASS I RESTRICTED T CELL RESPONSE - Described are peptides and polypeptides derived from the MUC-1 polypeptide which are able to activate Cytotoxic T Lymphocyte (CTL) response, analogues of such peptides and polypeptides nucleotide sequences encoding such peptides and polypeptides and therapeutic uses thereof. Moreover, indications for selecting appropriate minimal antigenic MUC-1 polypeptides with reference to the HLA-type of the patient to be treated or tested are described. | 09-18-2008 |